Form 4: Rhythm Pharmaceuticals Director Jennifer L. Good Reports Stock Option and Restricted Stock Unit Grants

Director Jennifer L. Good reports the acquisition of stock options and restricted stock units in Rhythm Pharmaceuticals.

Summary

• On June 18, 2024, Jennifer L. Good, a director of Rhythm Pharmaceuticals, reported the acquisition of 14,000 stock options and 4,000 restricted stock units (RSUs).
• The stock options have an exercise price of $41.39 and expire on June 17, 2034.
• The options and RSUs fully vest upon the earlier of June 18, 2025, or the date of the Issuer's annual meeting of stockholders in 2025, contingent upon continued service.
• Each RSU represents a contingent right to receive one share of Rhythm Pharmaceuticals common stock and has no expiration date.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock options and restricted stock units grants, which is neutral in sentiment.

Industry Context

This filing is a routine disclosure of stock options and restricted stock units granted to a company director, which is a common practice in publicly traded companies to align the interests of management with those of shareholders.

Stakeholder Impact

• The grant of stock options and RSUs aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates